A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma
Open Access
- 12 August 2004
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 792-798
- https://doi.org/10.1111/j.1365-2141.2004.05127.x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant ProgramLeukemia & Lymphoma, 2003
- Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatmentBritish Journal of Haematology, 2002
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- A phase I/II trial of Z‐Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myelomaBritish Journal of Haematology, 1996
- VAD chemotherapy as remission induction for multiple myelomaBritish Journal of Cancer, 1995
- Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosisThe Lancet, 1992
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983